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Fig 2. Secondary patency rates by KM analysis were 93.8% at 12 months,
93.8% at 24 months, and 89.3% at 36 months.
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Evolution of Gender-Related Differences in Outcomes From Two
Decades of Endovascular Aneurysm Repair (EVAR)
Christine Chung, MD, Ageliki Vouyouka, MD, Rami Tadros, MD, Marielle
Torres, BA, Daniel Han, MD, Rajesh Malik, MD, Peter Faries, MD,
Michael Marin, MD. Division of Vascular Surgery, Mount Sinai School of
Medicine, New York, NY
Objectives: Women are under-represented in trials that set guidelines
for aortic aneurysm management. Several studies reported inferior outcomes
in women compared with men after endovascular aneurysm repair (EVAR).
We investigated the relationship between gender and outcomes after EVAR.
Methods: A total of 1380 consecutive patients underwent elective
EVAR from 1992 to 2012. Baseline, intraoperative, and postoperative vari-
ables were analyzed from a prospective database.
Results: The cohort consisted of 214 women (15.5%) and 1166 men
(84.5%). Women were older than men at repair (77.8 vs 74.5 years; P <
.001) and had less cardiac disease (P ¼ .005). They had shorter (19.8 6
12.9 mm vs 26.3 6 14.7 mm; P < .001), more angulated aortic necks
(38.8 6 16.1 vs 31.2 6 14.7; P < .001) and fewer iliac aneurysms (P ¼
.002). Women had more arterial reconstructions (iliac conduits, P ¼ .006;
thrombolysis and thrombectomy,P¼ .013; patch angioplasty, P< .001; end-
arterectomy,P< .001),more perioperative complications (11.2% vs 6.3%;P¼
.009), and in-hospital days (4.1 days vs 3.4 days;P¼ .029). Perioperativemor-
tality was equivalent (women: 2% vsmen: 2.3%;P¼ .73).Mean follow-upwas
30.9 months. Women and men experienced equivalent endoleaks, arterial
reinterventions, aneurysm-related deaths, and overall survival.
Conclusions: Female gender is associated with more periprocedural
complications; however, it does not affect long-term reinterventions or survival.
Further studies are warranted to elucidate the effect of gender on outcomes.
This data should be considered when selecting EVAR for men and women.
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Midterm Results of Stenting of Femoropopliteal Lesions Using
Interwoven Nitinol Stents
Alexander A. Brescia,1 Juan Carlos Correa, MD,1 Brian Wickers,1 Matthew
R. Smeds, MD,2 Donald L. Jacobs, MD1. 1Department of Surgery, Division
of Vascular Surgery, St. Louis University Hospital, St. Louis, Mo; and
2University of Arkansas, Little Rock, ArkFig 1. Primary patency rates by KM analysis were 85.6% at 12 months,
83.1% at 24 months, and 76.7% at 36 months.Objectives: The Supera stent (Abbott Laboratories, Abbott Park, Ill)
has a unique biomimetic design allowing for axial and longitudinal ﬂexibility
and fracture resistance. The aim of this retrospective study was to assess the
midterm primary patency of Supera stents used to treat patients with super-
ﬁcial femoral and popliteal arterial disease by a single practice.
Methods: From April 2010 to December 2011, 48 patients and 54
limbs with symptomatic femoropopliteal lesions underwent angioplasty
and stenting with the Supera stent. Five patients had no follow-up and
were excluded. Patient demographics, radiographic imaging, lesion mor-
phologies, procedural reports, reinterventions, and follow-up clinical visit
notes were reviewed. Primary patency was deﬁned as clinical resolution of
symptoms and no secondary intervention. The 12-, 24-, and 36-month pri-
mary and secondary patency rates were estimated using Kaplan-Meier
analysis.
Results: A total of 48 consecutive patients (42 males, six females),
54 limbs, mean age 64.3 years (range, 51-87 years) received Supera stents as
part of their treatment for femoropopliteal disease.Primary indications for inter-
vention included claudication, rest pain, and tissue loss at rates of 54% (29 of
54), 26% (14 of 54), and 20% (11 of 54), respectively. Twenty-two percent
of lesions were TransAtlantic Inter-Society Consensus (TASC) A or B, and
78% were C or D. Mean lesion length was 24.0 cm (range, 3-51 cm). Mean
follow-up was 27.5 months (range, 1-45). The ankle-brachial index increased
from 0.58 6 0.20 preoperatively to 0.77 6 0.18 postoperatively (P ¼
.00004). Primary, primary assisted, and secondary patency rates at the latest
follow-up were 79.6%, 88.9%, and 92.3%, respectively (Table). Long lesions
>30 cm (33%; 18/54) had primary, primary-assisted, and secondary patency
rates at latest follow-upof 83%, 89%, and 94%, respectively.Cumulative primary
patency rates by Kaplan-Meier analysis at 12, 24, and 36 months was 85.6%,
83.1%, and 76.7%, respectively (Fig 1). Secondary patency rates by Kaplan-
Meier estimates at 12, 24, and 36 months were 93.8%, 93.8%, and 89.3%,
respectively (Fig 2). No stent fractures were found at clinical follow-up.
Conclusions: Our midterm results show that Supera stents are dura-
ble in treating femoropopliteal lesions, with notably high patency rates in
long lesions.
Table. Patency rates as a function of lesion length
1-15 cm 16-30 cm >30 cmPatency
(n ¼ 18),
No. (%)(n ¼ 18),
No. (%)(n ¼ 18),
No. (%)Primary patency 13 (72.2) 15 (83.3) 15 (83.3)
Primary-assisted patency 16 (88.9) 16 (88.9) 16 (88.9)
Secondary patency 17 (94.4) 16 (88.9) 17 (94.4)
Table. Discriminatory value of aortic neck anatomic variables
Variables
Success
(No EL/MIG)
(n ¼ 140)
Failure
(EL/MIG)
(n ¼ 82)
Optimal
threshold P value
EVAR + EndoAnchors, No. 140 3
EVAR alone, No 0a 79
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Cilostazol and Freedom From Amputation After Lower Extremity
Revascularization
J. David Neel, MD,1 Robin L. Kruse, PhD,1 Viktor Y.
Dombrovskiy, PhD,2 Todd R. Vogel, MD1. 1University of Missouri
Hospitals & Clinics, Columbia, Mo; 2Rutgers Robert Wood Johnson
Medical School, NJ
Objectives: Cilostazol, an antiplatelet agent with vasodilating
properties, has not been well evaluated in conjunction lower extremity
revascularization (LER). We evaluated the association between cilosta-
zol and limb salvage after endovascular (ENDO) or open surgery
(OPEN) for lower extremity revascularization (LER).
Methods: Patients aged $65 years undergoing LER were iden-
tiﬁed from 2007 to 2008 MedPAR ﬁles using International Classi-
ﬁcation of Diseases, 9th Revision codes. Demographics,
comorbidities, and disease severity were obtained. Postprocedural
use of cilostazol was identiﬁed using National Drug Codes and Part
D ﬁles. Outcomes were compared using c2 analysis, Kaplan-Meier,
and Cox regression.
Results: We identiﬁed 22,954 patients undergoing LER: 8128
patients (35.4%) with claudication, 3056 (13.3%) with rest pain,
and 11,770 (51.28%) with ulceration/gangrene, and 2972 (13.0%)
patients were identiﬁed using cilostazol after LER. More patients
received ENDO (14,353) than OPEN (8601) procedures. Cilostazol
users had fewer amputations compared with nonusers at 30 days
(7.8% vs 13.4%), 90 days (10.6% vs 18.0%), and 1 year (14.8% vs
24.0%; P < .0001 for all; Fig). Compared with nonusers, patients tak-
ing cilostazol had signiﬁcantly fewer 1-year crude amputation rates:
15.0% vs 23.1% (P < .0001) for ENDO and 14.5% vs 21.7% (P <
.0001), for OPEN. In Cox proportional hazards regression with
adjustment for age, gender, race, comorbidities, type of procedure,
and atherosclerosis severity, noncilostazol users were more likely to
undergo amputation during 1 year after surgery (hazard ratio [HR],
1.15; 95% conﬁdence interval [CI], 1.02-1.23; P ¼ .02). Subset anal-
ysis revealed, noncilostazol users with renal failure (HR, 1.61; 95%
CI, 1.28-2.02; P < .0001) or diabetes (HR, 1.61; 95% CI, 1.36-
1.92; P < .0001) were more likely to undergo amputation during 1
year after surgery.
Conclusions: In patients undergoing LER, cilostazol use
was associated with improved 1-year freedom from amputation. Patients
with renal failure and diabetes demonstrated an even greater beneﬁt of cil-
ostazol use on freedom from amputation. Further studies are needed to
evaluate the beneﬁts of cilostazol after intervention.Fig. 1-year Freedom of amputation after lower extremity revascularization
with and without Cilostazol.
Neck length, mm 23 6 17 18 6 14 >18 .037
Neck diameter, mm 26 6 3 28 6 5 <26 .009
Infrarenal angulation, 36 6 18 35 6 16 <33 .774
Conicity, % increase/mm 1.1 6 0.9 1.4 6 1.1 >1.0 .545
Thrombus, mm 0.9 6 1.4 0.4 6 0.8 >1 .693
Calcium, mm 1.0 6 1.2 1.3 6 1.3 <1 .615
EL, Endoleak; EVAR, endovascular aneurysm repair; MIG, migration.
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Outcome-Based Anatomic Criteria for Deﬁning the Hostile Aortic
Neck
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Objectives: There is ample evidence linking aortic neck anatomy
to poor outcome after endovascular aortic aneurysm repair (EVAR),
yet the deﬁnition of hostile anatomy varies from study to study.
This current analysis was undertaken to determine which anatomic
criteria are most predictive of failure of proximal neck sealing and ﬁx-
ation after EVAR.
Methods: The study group comprised patients in the ANCHOR
clinical trial. Core laboratory analysis of three-dimensional centerline-
reformatted computed tomography (CT) scans were assessed for aortic
neck length, neck diameter, infrarenal angulation, conical conﬁguration
(percentage increase in neck diameter per mm neck length), and mural
thrombus/calcium thickness. Success or failure at the aortic neck was
deﬁned by type Ia endoleak (EL) or migration (MIG). Receiver operating
characteristic curve analysis was used to determine the optimal threshold
for discriminating success from failure. The areas under the curve were
analyzed for each anatomic variable, and signiﬁcance was assumed when
P was <.05.
Results: A total of 222 patients were included in the study: 79
(35.6%) for EndoAnchor treatment of EL/MIG in previously placed
endografts and 143 (64.4%) for EndoAnchor prophylaxis against EL/
MIG in patients with investigator-determined challenging neck anatomy.
Within the latter group, three of 143 (1.7%) subsequently failed at the
proximal neck. Over an average imaging follow-up of 9 months (range,
0-180 months), 140 of 222 patients (63.1%) were free from EL or
MIG after EVAR (success), whereas 82 (36.9%) were not (failures).
Aortic neck anatomic variables associated with success or failure are listed
in the Table.
Conclusions: Infrarenal neck diameter and length appear to be
the best differentiators of success from failure at the aortic neck.
The optimal thresholds identiﬁed by receiver operating characteristic
curve analysis should be considered when deﬁning the hostile aortic
neck.Author Disclosures: W. Jordan: Honoraria, institution receives research
funding from Aptus. K. Ouriel: Other ﬁnancial beneﬁt, is employed by
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Morbidity and Mortality After Use of an Iliac Conduit for
Endovascular Aortic Aneurysm Repair
Prateek K. Gupta, MD, K. Craig Kent, MD. Surgery, University of
Wisconsin Hospital and Clinics, Madison, Wisc
Objectives: Although it is generally felt that placement of an iliac
conduit for endovascular aortic aneurysm repair (EVAR) results in higher
morbidity and mortality, published literature is scarce. Our objective was
to assess 30-day outcomes after elective EVAR with an iliac conduit using
a multi-institutional database.
